Scotia Capital Inc. Reduces Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Scotia Capital Inc. reduced its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 11.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,363 shares of the financial services provider’s stock after selling 1,196 shares during the quarter. Scotia Capital Inc.’s holdings in iShares Biotechnology ETF were worth $1,238,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IBB. Bessemer Group Inc. increased its position in iShares Biotechnology ETF by 225.4% during the fourth quarter. Bessemer Group Inc. now owns 3,075 shares of the financial services provider’s stock valued at $407,000 after acquiring an additional 2,130 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of iShares Biotechnology ETF during the 4th quarter worth about $1,732,000. FIL Ltd grew its holdings in iShares Biotechnology ETF by 1.5% during the 4th quarter. FIL Ltd now owns 14,693 shares of the financial services provider’s stock valued at $1,943,000 after purchasing an additional 215 shares during the last quarter. Cerity Partners LLC raised its position in iShares Biotechnology ETF by 1.5% in the 4th quarter. Cerity Partners LLC now owns 50,954 shares of the financial services provider’s stock worth $6,739,000 after purchasing an additional 741 shares during the period. Finally, Hurley Capital LLC bought a new stake in iShares Biotechnology ETF in the fourth quarter worth about $59,000. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Stock Performance

IBB opened at $116.96 on Monday. iShares Biotechnology ETF has a one year low of $107.43 and a one year high of $150.57. The stock has a market cap of $5.36 billion, a price-to-earnings ratio of 24.21 and a beta of 0.84. The stock’s 50 day moving average price is $131.74 and its 200-day moving average price is $136.61.

iShares Biotechnology ETF Increases Dividend

The firm also recently announced a dividend, which was paid on Friday, March 21st. Shareholders of record on Tuesday, March 18th were paid a $0.1212 dividend. This is a positive change from iShares Biotechnology ETF’s previous dividend of $0.06. The ex-dividend date was Tuesday, March 18th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.